Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT03208465
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT03208465
-
- Other papers using this trial's data
- Comparison of empagliflozin and sitagliptin therapy on myocardial perfusion reserve in diabetic patients with coronary artery disease
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03208465. Randomized; no masking; primary purpose treatment. Start 2017-08-07 (actual); primary completion 2019-08-01 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
- Acronym
- ELITE
- Condition
- Diabetes Mellitus
- Condition
- Coronary Disease
- Intervention (Drug)
- Empagliflozin
- Intervention (Drug)
- Sitagliptin
- Lead sponsor
- CHEOL WHAN LEE, M.D., Ph.D
Record details
- Record id
cardio:ct-nct03208465- Content hash
937ecf69ab1464f6c2aadcf5a3dd87407915fc92c0591bdaba3ae8a94fa93de0